Formulation and in-vitro evaluation of oxaprozin transdermal patches for sustained anti-inflammatory therapy

Mansi Gupta; Priya  Tiwari

doi:10.69857/joapr.v13i6.1203

Authors

Mansi Gupta Moradabad Educational Trust, Group of Institutions, Faculty of Pharmacy, Moradabad, UP, India, 244001
Priya Tiwari Moradabad Educational Trust, Group of Institutions, Faculty of Pharmacy, Moradabad, UP, India, 244001

DOI:

https://doi.org/10.69857/joapr.v13i6.1203

Keywords:

Oxaprozin (OXA), Transdermal Patches, NSAIDs, Rheumatoid Arthritis, Box-Behnken Design, Drug release

Abstract

Background: Inflammation is characterized by pain, altered membrane permeability, increased vascular activity, and protein denaturation. Oxaprozin, a BCS Class II NSAID, is often used to manage inflammation and pain but is limited by poor solubility and extensive first-pass metabolism, which reduces its effectiveness when administered orally. This study aimed to develop and evaluate oxaprozin-loaded transdermal patches as a patient-friendly alternative for sustained anti-inflammatory therapy. Methodology: Transdermal patches were formulated using the solvent-casting technique with hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidone (PVP K-30) as film-forming polymers, along with plasticizers and permeation enhancers (propylene glycol and DMSO). A Box-Behnken design (13 runs) was employed to optimize the effects of polymer concentrations on adhesion strength and % cumulative drug release. The patches were characterized for thickness, folding endurance, surface pH, moisture content, drug content, and in vitro drug release. Result and Discussion: Pre-formulation studies confirmed drug-excipient compatibility and stability. P1 exhibited optimal performance with a thickness (0.123±0.34 mm), weight variation (94.5±0.56 %), drug content (94.47 %), folding endurance (25±0.1), and in vitro drug release (81.14±6.08 % over 24 hours). The release followed Korsmeyer-Peppas kinetics (R² = 0.9677), indicating a diffusion-controlled release mechanism. Statistical analysis confirmed significant differences among formulations (p < 0.05) & stability studies showed no changes after 3 months. Conclusion: The optimized oxaprozin transdermal patches, particularly formulation P1, demonstrated uniformity, stability, and controlled drug release, establishing their potential as an effective alternative to oral NSAID therapy. Future in vivo studies are recommended to confirm therapeutic efficacy and clinical applicability.

Downloads

Download data is not yet available.

References

Chavan YS. Development and Optimization of Transdermal Patches of Losartan Potassium. Asian J. Pharm. Technol., 15, 119–26 (2025) https://doi.org/10.52711/2231-5713.2025.00020.

Choudhury D, Dutta KN, Kalita R. A review on transdermal patches used as an anti-inflammatory agent. Asian J Pharm Clin Res, 14, 21–6 (2021) http://dx.doi.org/10.22159/ajpcr.2021v14i12.43277.

Anubha Dhuriya and Aaditya Singh. Evalaution of Antidepressant and Anxiolytic Activity of Oxaprozin in Swiss Albino Mice. Int. J. Adv. Res., 11, 295–304 (2023) https://dx.doi.org/10.21474/IJAR01/16880.

Karim A, Noveck R, McMahon FG, Smith M, Crosby S, Adams M, Wilton J. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half‐lives: effect of protein‐binding differences on steady‐state pharmacokinetics. J. Clin. Pharmacol., 37, 267–78 (1997) https://doi.org/10.1002/j.1552-4604.1997.tb04302.x.

Aitipamula S, Wong ABH, Chow PS, Tan RBH. Novel solid forms of oxaprozin: cocrystals and an extended release drug–drug salt of salbutamol. RSC Adv., 6, 34110–9 (2016) https://doi.org/10.1039/C6RA01802E.

Koli, Ramachandra, Phoolsingh Yaduwanshi. Jyotiram Sawale RS. Design And Evaluation Of Transdermal Drug Delivery System Of Selected Cardiovascular Drug. African J. Biomed. Res., 26, 457–66 (2023) https://doi.org/10.53555/AJBR.v26i3.7173.

Wable SA, Pingale PL, Shinkar DM, Boraste SS, Amrutkar S V. Formulation, Optimization, and Evaluation of Transdermal Patches of Clotrimazole and Betamethasone Dipropionate for Candidiasis. Res. J. Pharm. Technol., 17, 4267–74 (2024) https://doi.org/10.52711/0974-360X.2024.00660.

Purohit P V, Pakhar PS, Pawar VB, Dandade SS, Waghmare MS, Shaikh FA, Kale RH. Formulation and Comparative Evaluation of Naproxen-Based Transdermal Gels. J. Pharm. Sci. Comput. Chem, 1, 83–105 (2025) https://doi.org/10.32553/ijmbs.v8i1.2765.

Arya U, Malik JK. Preformulation studies of aceclofenac: Major part of formulation strategy. EAS J Pharm Pharmacol, 4, 91–5 (2022) https://doi.org/10.36349/easjpp.2022.v04i06.001.

Chopra N, Chaudhuri A, Kumar H, Gurjar A, Sharma N. Development and Characterization of Self-healing Transdermal Patch of Lidocaine for the Management of Pain. Curr. Res. Pharm. Sci., 108–17 (2023) https://doi.org/10.24092/CRPS.2023.130204.

Shehata TM, Mohafez O, Hanieh HN. Pharmaceutical formulation and biochemical evaluation of atorvastatin transdermal patches. Indian J. Pharm. Educ. Res, 52, 54–61 (2018) https://doi.org/http://dx.doi.org/10.5530/ijper.52.1.6.

Patel P, Ahir K, Patel V, Manani L, Patel C. Drug-Excipient compatibility studies: First step for dosage form development. Pharma Innov., 4, 14 (2015).

Bhatia C, Sachdeva M, Bajpai M. Formulation and evaluation of transdermal patch of pregabalin. Int. J. Pharm. Sci. Res., 3, 569 (2012) http://dx.doi.org/10.13040/IJPSR.0975-8232.3(2).569-75.

Jajoo VS, Shrirame DS, Sawale A V, Atram SC. Formulation and evaluation of Transdermal Patch for the treatment of Migraine. J. Drug Deliv. Ther., 13, 47–52 (2023) http://dx.doi.org/10.22270/jddt.v13i5.6072.

Shelke P V, Rachh PR, Mankar SD, Gorde PL. Optimization and evaluation of transdermal delivery system for nebivolol hydrochloride. J. Appl. Pharm. Res., 12, 21–37 (2024) https://doi.org/10.69857/joapr.v12i3.580.

Mo L, Lu G, Ou X, Ouyang D. Formulation and development of novel control release transdermal patches of carvedilol to improve bioavailability for the treatment of heart failure. Saudi J. Biol. Sci., 29, 266–72 (2022) https://doi.org/10.1016/j.sjbs.2021.08.088.

Karnakoti A, Borade A, Birajdar P, Bodke V, Dagale M, Badekar R. Formulation and Evaluation of Transdermal Patch. Int. J. Sci. Res. Technol., (2025) https://doi.org/10.5281/zenodo.14837862.

Jacob L, Salim MS, Saju J. Formulation and evaluation of transdermal patches of selegiline. Asian J. Pharm. Technol., 12, 96–100 (2022) https://doi.org/10.52711/2231-5713.2022.00016.

Sk V, Pashikanti S. Design , Development , and Evaluation of Transdermal Patches Containing Donepezil Hydrochloride. Int. J. Drug Deliv. Technol., 13, 576–83 (2023) https://doi.org/10.25258/ijddt.13.2.18.

Nandi S, Mondal S. Fabrication and evaluation of matrix type novel transdermal patch loaded with tramadol hydrochloride. Turkish J. Pharm. Sci., 19, 572 (2022) https://doi.org/10.4274/tjps.galenos.2021.43678.

Kumar M, Bose P, Singh AP, Singh AP. Formulation And Evaluation of Betulinic Acid Loaded Transdermal Patches. J. Drug Deliv. Ther., 15, 52–8 (2025) http://dx.doi.org/10.22270/jddt.v15i1.6951.

Dhaval J. Patel, Saurav M. Patel, Sanjesh G. Rathi SKS. Formulation and Evaluation of Transdermal Patch of Blonanserin. Int. J. Pharm. Sci. Rev. Res., 69, 69–74 (2021) https://doi.org/10.47583/ijpsrr.2021.v69i02.011.

Shoaib MH, Tazeen J, Merchant HA, Yousuf RI. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Pak. J. Pharm. Sci., 19, 119–24 (2006).

Ashok BK, Sominath WJ. Formulation and Evaluation of Transdermal Patches of Tridax Procumbenes for Anti-Inflammatory Activity. Int. J. Pharm. Res. Appl., 9, 1784–97 (2024) https://doi.org/10.35629/7781-090217841797.